CN109575121A - Identify the T cell receptor of AFP antigen small peptide - Google Patents

Identify the T cell receptor of AFP antigen small peptide Download PDF

Info

Publication number
CN109575121A
CN109575121A CN201710900629.5A CN201710900629A CN109575121A CN 109575121 A CN109575121 A CN 109575121A CN 201710900629 A CN201710900629 A CN 201710900629A CN 109575121 A CN109575121 A CN 109575121A
Authority
CN
China
Prior art keywords
tcr
ser
cell
seq
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201710900629.5A
Other languages
Chinese (zh)
Other versions
CN109575121B (en
Inventor
李懿
胡静
相瑞瑞
孙含丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangxue Life Science Technology Guangdong Co ltd
Original Assignee
Guangdong Xiangxue Precision Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Xiangxue Precision Medical Technology Co Ltd filed Critical Guangdong Xiangxue Precision Medical Technology Co Ltd
Priority to CN201710900629.5A priority Critical patent/CN109575121B/en
Publication of CN109575121A publication Critical patent/CN109575121A/en
Application granted granted Critical
Publication of CN109575121B publication Critical patent/CN109575121B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

The present invention provides the T cell receptor (TCR) that one kind can specifically bind the small peptide FMNKFIYEI derived from AFP antigen, the antigen small peptide FMNKFIYEI can form compound with HLA A0201 and be presented to cell surface together.Carrier the present invention also provides the nucleic acid molecules for encoding the TCR and comprising the nucleic acid molecules.In addition, the present invention also provides the cells for the TCR of the present invention that transduces.

Description

Identify the T cell receptor of AFP antigen small peptide
Technical field
The present invention relates to that can identify the TCR from AFP antigen small peptide, the invention further relates to transduce above-mentioned TCR to obtain AFP specificity T cell and they prevent and treat AFP related disease in purposes.
Background technique
AFP (α Fetoprotein) is also referred to as alpha fetal protein, is a kind of albumen expressed in embryo development procedure, is fetal blood Clear main component.In growth course, AFP has relatively high expression in yolk bag and liver, is then suppressed. In hepatocellular carcinoma, the expression of AFP be activated (Butterfield et al. J Immunol., 2001, Apr 15；166 (8):5300-8).AFP is degraded to micromolecule polypeptide after generating in the cell, and with MHC (main histocompatibility complex) Molecule combines and forms compound, is presented to cell surface.FMNKFIYEI (SEQ ID NO:9) is derived from AFP antigen Small peptide is a kind of target of AFP treating correlative diseases.
T cell adoptive immunotherapy is that will there is the reaction-ive T cell of specificity to be transferred to patient body target cell antigen It is interior, so that it is played a role for target cell.T cell receptor (TCR) is a kind of memebrane protein on T cell surface, can identify phase The antigen small peptide for the target cell surface answered.In immune system, pass through TCR and the main tissue phase of small peptide-of antigen small peptide specificity The combination of capacitive complex (pMHC compound) causes T cell and antigen presenting cell (APC) is directly physically contacted, then T Other cell membrane surface molecules of both cell and APC just interact, and cause a series of subsequent cell signals transmitting With other physiological reactions so that the T cell of different antigentic specificity plays immunological effect to its target cell.Therefore, ability Field technique personnel are dedicated to isolating the TCR for having specificity to AFP antigen small peptide, and the TCR is transduceed T cell to obtain The T cell that there is specificity to AFP antigen small peptide is obtained, so that them be made to play a role in cellular immunotherapy.
Summary of the invention
The purpose of the present invention is to provide a kind of T cell receptors for identifying AFP antigen small peptide.
The first aspect of the present invention, provides a kind of T cell receptor (TCR), and the TCR can be with FMNKFIYEI-HLA A0201 compound combines.
In another preferred example, the TCR includes TCR α chain variable domain and TCR β chain variable domain, and the TCR α chain is variable The amino acid sequence of the CDR3 in domain is ATDPRTGANSKLT (SEQ ID NO:12)；And/or the TCR β chain variable domain The amino acid sequence of CDR3 is ASEGLAYEQY (SEQ ID NO:15).
In another preferred example, 3 complementary determining regions (CDR) of the TCR α chain variable domain are as follows:
α CDR1-TSINN (SEQ ID NO:10)
α CDR2-IRSNERE (SEQ ID NO:11)
α CDR3-ATDPRTGANSKLT (SEQ ID NO:12)；And/or
3 complementary determining regions of the TCR β chain variable domain are as follows:
β CDR1-SEHNR (SEQ ID NO:13)
β CDR2-FQNEAQ (SEQ ID NO:14)
β CDR3-ASEGLAYEQY (SEQ ID NO:15)。
In another preferred example, the TCR includes TCR α chain variable domain and TCR β chain variable domain, and the TCR α chain is variable Domain is the amino acid sequence for having at least 90% sequence identity with SEQ ID NO:1；And/or the TCR β chain variable domain is There is the amino acid sequence of at least 90% sequence identity with SEQ ID NO:5.
In another preferred example, the TCR includes α chain variable domain amino acid sequence SEQ ID NO:1.
In another preferred example, the TCR includes β chain variable domain amino acid sequence SEQ ID NO:5.
In another preferred example, the TCR is α β heterodimer, and it includes TCR α chain constant region TRAC*01 and TCR β Chain constant region TRBC1*01 or TRBC2*01.
In another preferred example, the α chain amino acid sequence of the TCR is the β chain of the SEQ ID NO:3 and/or TCR Amino acid sequence is SEQ ID NO:7.
In another preferred example, the TCR is soluble.
In another preferred example, the TCR is single-stranded.
In another preferred example, the TCR is connect with β chain variable domain by peptide catenation sequence by α chain variable domain At.
In another preferred example, the TCR in α chain variable region amino acid the 11st, 13,19,21,53,76,89,91 or There is one or more in 94th and/or α chain J gene small peptide amino acid inverse the 3rd, 5th reciprocal or 7th reciprocal Mutation；And/or the TCR is in β chain variable region amino acid the 11st, 13,19,21,53,76,89,91 or the 94th and/or β In chain J gene small peptide amino acid inverse the 2nd, 4th reciprocal or 6th reciprocal there is one or more to be mutated, wherein amino Sour Position Number is by the Position Number listed in IMGT (international immunogenetics information system).
In another preferred example, the α chain variable domain amino acid sequence of the TCR includes SEQ ID NO:32 and/or described The β chain variable domain amino acid sequence of TCR includes SEQ ID NO:34.
In another preferred example, the amino acid sequence of the TCR is SEQ ID NO:30.
In another preferred example, the TCR includes (a) all or part of TCR α chain in addition to transmembrane domain；And (b) all or part of TCR β chain in addition to transmembrane domain；
And (a) and (b) respectively contains functional variable domain, or includes functional variable domain and the TCR At least part of chain constant domain.
In another preferred example, cysteine residues form artificial two sulphur between α the and β chain constant domain of the TCR Key.
In another preferred example, the cysteine residues of artificial disulfide bond are formed in the TCR instead of selected from following One or more groups of sites:
The Ser57 of Thr48 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；
The Ser77 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；
The Ser17 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；
The Asp59 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；
The Glu15 of Ser15 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；
The Ser54 of Arg53 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；
The Ala19 of Pro89 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；With
The Glu20 of Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1.
In another preferred example, the α chain amino acid sequence of the TCR is the β chain of the SEQ ID NO:26 and/or TCR Amino acid sequence is SEQ ID NO:28.
In another preferred example, artificial interchain disulfide bond is contained between the α chain variable region of the TCR and β chain constant region.
In another preferred example, which is characterized in that the cysteine that artificial interchain disulfide bond is formed in the TCR is residual Base is instead of selected from following one or more groups of sites:
The 46th amino acids of TRAV and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1；
The 47th amino acids of TRAV and 61 amino acids of TRBC1*01 or TRBC2*01 exons 1；
The 46th amino acids of TRAV and the 61st amino acids of TRBC1*01 or TRBC2*01 exons 1；Or
The 47th amino acids of TRAV and the 60th amino acids of TRBC1*01 or TRBC2*01 exons 1.
In another preferred example, the TCR is comprising α chain variable domain and β chain variable domain and in addition to transmembrane domain All or part of β chain constant domain, but it does not contain α chain constant domain, the α chain variable domain and β chain of the TCR forms heterogeneous dimerization Body.
In another preferred example, the α chain of the TCR and/or the end C- or N- of β chain are combined with conjugate.
In another preferred example, the conjugate in conjunction with the T cell receptor is detectable marker, therapeutic agent, PK are repaired The combination of decorations part or any of these substances.Preferably, the therapeutic agent is anti-CD 3 antibodies.
The second aspect of the present invention provides a kind of multivalent TCR complex, and it includes at least two TCR molecules, and At least one TCR molecule therein is TCR described in first aspect present invention.
The third aspect of the present invention, provides a kind of nucleic acid molecules, and the nucleic acid molecules include to encode first party of the present invention The nucleic acid sequence of TCR molecule or its complementary series described in face.
In another preferred example, the nucleic acid molecules include the nucleotide sequence SEQ ID NO of coding TCR α chain variable domain: 2 or SEQ ID NO:33.
In another preferred example, the nucleic acid molecules include the nucleotide sequence SEQ ID of coding TCR β chain variable domain NO:6 or SEQ ID NO:35.
In another preferred example, the nucleic acid molecules include coding TCR α chain nucleotide sequence SEQ ID NO:4 and/ Or the nucleotide sequence SEQ ID NO:8 comprising encoding TCR β chain.
The fourth aspect of the present invention, provides a kind of carrier, and the carrier contains core described in third aspect present invention Acid molecule；Preferably, the carrier is viral vectors；It is highly preferred that the carrier is slow virus carrier.
The fifth aspect of the present invention provides a kind of isolated host cell, contains the present invention in the host cell Nucleic acid molecules described in the third aspect present invention of external source are integrated in carrier described in fourth aspect or genome.
The sixth aspect of the present invention provides a kind of cell, nucleic acid described in the cell transduction third aspect present invention Carrier described in molecule or fourth aspect present invention；Preferably, the cell is T cell or stem cell.
The seventh aspect of the present invention, provides a kind of pharmaceutical composition, and the composition contains pharmaceutically acceptable load TCR described in body and first aspect present invention, TCR compound described in second aspect of the present invention, third aspect present invention institute Cell described in carrier described in the nucleic acid molecules stated, fourth aspect present invention or sixth aspect present invention.
The eighth aspect of the present invention provides T cell receptor described in first aspect present invention or second party of the present invention Nucleic acid molecules described in TCR compound, third aspect present invention described in face, carrier described in fourth aspect present invention or sheet The purposes for inventing cell described in the 6th aspect, is used to prepare the drug for the treatment of tumour or autoimmune disease.
The ninth aspect of the present invention provides a kind of method for treating disease, including suitable to object in need for the treatment of application TCR compound, third of the present invention described in T cell receptor described in the first aspect present invention of amount or second aspect of the present invention Nucleic acid molecules described in aspect, cell described in carrier or sixth aspect present invention described in fourth aspect present invention or sheet Invent pharmaceutical composition described in the 7th aspect；
Preferably, the disease is tumour, and the preferably described tumour is hepatocellular carcinoma.
It should be understood that above-mentioned each technical characteristic of the invention and having in below (eg embodiment) within the scope of the present invention It can be combined with each other between each technical characteristic of body description, to form a new or preferred technical solution.As space is limited, Not repeated them here.
Detailed description of the invention
Fig. 1 a, Fig. 1 b, Fig. 1 c, Fig. 1 d, Fig. 1 e and Fig. 1 f are respectively that TCR α chain variable domain amino acid sequence, TCR α chain can Variable domain nucleotide sequence, TCR α chain amino acid sequence, TCR α chain nucleotide sequence, the TCR α chain amino acid with leader sequence Sequence and TCR α chain nucleotide sequence with leader sequence.
Fig. 2 a, Fig. 2 b, Fig. 2 c, Fig. 2 d, Fig. 2 e and Fig. 2 f are respectively that TCR β chain variable domain amino acid sequence, TCR β chain can Variable domain nucleotide sequence, TCR β chain amino acid sequence, TCR β chain nucleotide sequence, the TCR β chain amino acid with leader sequence Sequence and TCR β chain nucleotide sequence with leader sequence.
Fig. 3 is the CD8 of monoclonal cell+And the double positive staining results of the tetramer-PE.
Fig. 4 a and Fig. 4 b are respectively the amino acid sequence and nucleotide sequence of sTCR α chain.
Fig. 5 a and Fig. 5 b are respectively the amino acid sequence and nucleotide sequence of sTCR β chain.
Fig. 6 is the glue figure of the sTCR obtained after purification.Leftmost side swimming lane is to go back virgin rubber, and intermediate swimming lane is molecular weight It marks (marker), rightmost side swimming lane is non-reduced glue.
Fig. 7 a and Fig. 7 b are respectively the amino acid sequence and nucleotide sequence of single-stranded TCR.
Fig. 8 a and Fig. 8 b are respectively the amino acid sequence and nucleotide sequence of single-stranded TCR α chain.
Fig. 9 a and Fig. 9 b are respectively the amino acid sequence and nucleotide sequence of single-stranded TCR β chain.
Figure 10 a and Figure 10 b are respectively the amino acid sequence and nucleotide sequence of single-stranded TCR catenation sequence (linker).
Figure 11 is the glue figure of the soluble single-chain T CR obtained after purification.Left side swimming lane is molecular weight marker (marker), Right lanes are non-reduced glue.
Figure 12 is BIAcore dynamics of the sTCR of the present invention in conjunction with FMNKFIYEI-HLA A0201 compound Map.
Figure 13 is dynamic for BIAcore of the soluble single-chain T CR of the present invention in conjunction with FMNKFIYEI-HLA A0201 compound Mechanics map.
The ELISPOT for the T cell clone that Figure 14 is activates functional verification result.
Figure 15 do not transduce TCR of the invention effector cell ELISPOT activation functional verification result
Specific embodiment
The present inventor after extensive and in-depth study, have found with AFP antigen small peptide FMNKFIYEI (SEQ ID NO: 9) TCR that can be specifically bound, the antigen small peptide FMNKFIYEI can form compound with HLA A0201 and be in together It is delivered to cell surface.Carrier the present invention also provides the nucleic acid molecules for encoding the TCR and comprising the nucleic acid molecules. In addition, the present invention also provides the cells for the TCR of the present invention that transduces.
Term
MHC molecule is the protein of immunoglobulin superfamily, can be I class or class Ⅱ[MHC.Therefore, for The presentation of antigen has specificity, and different individuals has different MHC, can present small peptide different in a kind of proteantigen and arrive Respective APC cell surface.The MHC of the mankind is commonly referred to as HLA gene or HLA complex.
T cell receptor (TCR) is the unique of specific antigen peptide of the presentation on main histocompatibility complex (MHC) Receptor.In immune system, T cell is caused by the combination of the TCR and pMHC compound of antigentic specificity and antigen presentation is thin Born of the same parents (APC) are directly physically contacted, and then other cell membrane surface molecules of both T cell and APC just interact, This just causes a series of subsequent cell signal transmitting and other physiological reactions, so that the T of different antigentic specificities is thin Born of the same parents play immunological effect to its target cell.
TCR be as α chain/β chain or γ chain/δ chain in the form of heterodimer existing for cell membrane surface glycoprotein. TCR heterodimer is made of α and β chain in 95% T cell, and 5% T cell has the TCR being made of γ and δ chain. The natural heterogeneous dimerization TCR of α β has α chain and β chain, and α chain and β chain constitute the subunit of α β heterodimeric TCR.In a broad sense, α and Each chain of β includes variable region, bonding pad and constant region, and β chain usually contains short variable region also between variable region and bonding pad, But the variable region is often regarded as a part of bonding pad.Each variable region includes to be entrenched in frame structure (framework regions) In 3 CDR (complementary determining region), CDR1, CDR2 and CDR3.CDR region determines the combination of TCR and pMHC compound, wherein CDR3 is recombinated by variable region and bonding pad, referred to as hypervariable region.α the and β chain of TCR generally regards that each there are two " structures as Domain " i.e. variable domain and constant domain, variable domain are made of the variable region connected and bonding pad.The sequence of TCR constant domain can be in state It is found in the public database of border immunogenetics information system (IMGT), as the constant domain sequence of TCR molecule alpha chain is " TRAC*01 ", the constant domain sequence of TCR molecule β chain are " TRBC1*01 " or " TRBC2*01 ".In addition, α the and β chain of TCR is also Comprising transmembrane region and cytoplasmic region, cytoplasmic region is very short.
In the present invention, term " polypeptide of the present invention ", " TCR of the invention ", " T cell receptor of the invention " are interchangeable It uses.
Native interchain disulfide bond and artificial interchain disulfide bond
Natural TCR membrane-proximal region C α and C β interchain exist one group of disulfide bond, the present invention in referred to as " two sulphur of native interchain Key ".In the present invention, by what is be artificially introduced, the position interchain covalent disulfide bonds different from the position of native interchain disulfide bond claim For " artificial interchain disulfide bond ".
For convenience of the position of description disulfide bond, TRAC*01 and TRBC1*01 or TRBC2*01 amino acid sequence in the present invention Position Number by from N-terminal to C-terminal sequence successively carry out Position Number, in TRBC1*01 or TRBC2*01, by from N-terminal To the 60th amino acid of the sequence of C-terminal successively be P (proline), then the present invention in can describe it as TRBC1*01 or The Pro60 of TRBC2*01 exons 1 can also be stated that the 60th bit amino of TRBC1*01 or TRBC2*01 exons 1 Acid is Q (glutamine) by the 61st amino acid of the sequence from N-terminal to C-terminal successively for another example in TRBC1*01 or TRBC2*01, The Gln61 that TRBC1*01 or TRBC2*01 exons 1 can be then described it as in the present invention, can also be stated that TRBC1* 61st amino acids of 01 or TRBC2*01 exons 1, other and so on.In the present invention, the ammonia of variable region TRAV and TRBV The Position Number of base acid sequence, according to the Position Number listed in IMGT.Such as some amino acid in TRAV, listed in IMGT Position Number be 46, then the present invention in describe it as the 46th amino acids of TRAV, other and so on.In the present invention, The Sequence position numbers of his amino acid have specified otherwise, then press specified otherwise.
Detailed description of the invention
TCR molecule
In antigen processing pathways, antigen is degraded in the cell, is then carried by MHC molecule to cell surface.T Cell receptor can identify the peptide-MHC compound of Antigen Presenting Cell surface.Therefore, the first aspect of the present invention provides one Kind can be in conjunction with the TCR molecule of FMNKFIYEI-HLA A0201 compound.Preferably, the TCR molecule is separation or pure Change.α the and β chain of the TCR respectively has 3 complementary determining regions (CDR).
It is preferably carried out in mode at of the invention one, the α chain of the TCR includes with following amino acid sequence CDR:
α CDR1-TSINN (SEQ ID NO:10)
α CDR2-IRSNERE (SEQ ID NO:11)
α CDR3-ATDPRTGANSKLT (SEQ ID NO:12)；And/or
3 complementary determining regions of the TCR β chain variable domain are as follows:
β CDR1-SEHNR (SEQ ID NO:13)
β CDR2-FQNEAQ (SEQ ID NO:14)
β CDR3-ASEGLAYEQY (SEQ ID NO:15)。
The CDR region amino acid sequence of aforementioned present invention can be embedded into embedding to prepare in any suitable frame structure Close TCR.As long as frame structure is compatible with the CDR region of TCR of the invention, those skilled in the art disclosed CDR according to the present invention Area can design or synthesize the TCR molecule with corresponding function.Therefore, TCR molecule of the present invention refer to comprising above-mentioned α and/ Or the TCR molecule of β chain CDR region sequence and any suitable frame structure.TCR α chain variable domain of the present invention is and SEQ ID NO: 1 has at least 90%, preferably 95%, the more preferably amino acid sequence of 98% sequence identity；And/or TCR β of the present invention Chain variable domain is to have at least 90%, preferably 95%, the more preferably amino of 98% sequence identity with SEQ ID NO:5 Acid sequence.
In a preference of the invention, TCR molecule of the invention is the heterodimer being made of α and β chain.Tool Body, on the one hand the α chain of the heterogeneous dimerization TCR molecule includes variable domain and constant domain, the α chain variable domain amino acid sequence Column include CDR1 (SEQ ID NO:10), CDR2 (SEQ ID NO:11) and the CDR3 (SEQ ID NO:12) of above-mentioned α chain.It is preferred that Ground, the TCR molecule include α chain variable domain amino acid sequence SEQ ID NO:1.It is highly preferred that the α chain of the TCR molecule can Domain amino acid sequence is SEQ ID NO:1.On the other hand, the β chain of the heterogeneous dimerization TCR molecule includes variable domain and perseverance Localization, the β chain variable domain amino acid sequence include the CDR1 (SEQ ID NO:13) of above-mentioned β chain, CDR2 (SEQ ID NO: And CDR3 (SEQ ID NO:15) 14).Preferably, the TCR molecule includes β chain variable domain amino acid sequence SEQ ID NO: 5.It is highly preferred that the β chain variable domain amino acid sequence of the TCR molecule is SEQ ID NO:5.
In a preference of the invention, TCR molecule of the invention is by some or all of α chain and/or β chain The single chain TCR molecules partly or entirely formed.Description in relation to single chain TCR molecules can be with bibliography Chung et al (1994)Proc.Natl.Acad.Sci.USA 91,12654-12658.According to document, those skilled in the art's energy Enough easily buildings include the single chain TCR molecules in the area CDRs of the present invention.Specifically, the single chain TCR molecules include V α, V β and C β, preferably according to the sequential connection from N end to C-terminal.
CDR1 (SEQ ID NO:10) of the α chain variable domain amino acid sequence of the single chain TCR molecules comprising above-mentioned α chain, CDR2 (SEQ ID NO:11) and CDR3 (SEQ ID NO:12).Preferably, the single chain TCR molecules include α chain variable domain ammonia Base acid sequence SEQ ID NO:1.It is highly preferred that the α chain variable domain amino acid sequence of the single chain TCR molecules is SEQ ID NO:1.CDR1 (SEQ ID NO:13) of the β chain variable domain amino acid sequence of the single chain TCR molecules comprising above-mentioned β chain, CDR2 (SEQ ID NO:14) and CDR3 (SEQ ID NO:15).Preferably, the single chain TCR molecules include β chain variable domain Amino acid sequence SEQ ID NO:5.It is highly preferred that the β chain variable domain amino acid sequence of the single chain TCR molecules is SEQ ID NO:5。
In a preference of the invention, the constant domain of TCR molecule of the invention is the constant domain of people.This field skill Art personnel know or can by consult the public database of pertinent texts or IMGT (international immunogenetics information system) come Obtain the constant domain amino acid sequence of people.For example, the constant domain sequence of TCR molecule alpha chain of the present invention can be " TRAC*01 ", The constant domain sequence of TCR molecule β chain can be " TRBC1*01 " or " TRBC2*01 ".The amino provided in the TRAC*01 of IMGT The 53rd of acid sequence is Arg, is indicated herein are as follows: the Arg53 of TRAC*01 exons 1, other and so on.Preferably, originally The amino acid sequence of invention TCR molecule alpha chain is that the amino acid sequence of SEQ ID NO:3 and/or β chain is SEQ ID NO:7.
Naturally occurring TCR is a kind of memebrane protein, is stabilized by its transmembrane region.Such as immunoglobulin (antibody) The same as antigen recognition molecule, at this moment TCR can also need to obtain soluble TCR by development and application in diagnosing and treating Molecule.Soluble TCR molecule does not include its transmembrane region.STCR has very extensive purposes, it cannot be only used for studying The interaction of TCR and pMHC, it is also possible to make the diagnostic tool of detection infection or the marker as autoimmunity disease.It is similar Ground, sTCR can be used to therapeutic agent (such as cytotoxin compounds or immunostimulating compound) being transported to presentation The cell of specific antigen, in addition, sTCR can also be with other molecules (e.g., anti-CD 3 antibodies) in conjunction with redirecting T Cell, to make the cell of its targeting presentation specific antigen.The present invention, which is also obtained, has specificity to AFP antigen small peptide STCR.
To obtain sTCR, on the one hand, TCR of the present invention can be to be introduced between the residue of itself α and β chain constant domain The TCR of artificial disulfide bond.Cysteine residues form artificial interchain disulfide bond between α the and β chain constant domain of the TCR.Half Guang Histidine residue can be substituted in other amino acid residues of appropriate site in natural TCR to form artificial interchain disulfide bond.Example Such as, replace the Thr48 of TRAC*01 exons 1 and replace the cysteine of the Ser57 of TRBC1*01 or TRBC2*01 exons 1 Residue forms disulfide bond.Cysteine residues are introduced to form other sites of disulfide bond and may also is that TRAC*01 is aobvious outside The Ser77 of Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of son 1；The Tyr10 and TRBC1* of TRAC*01 exons 1 The Ser17 of 01 or TRBC2*01 exons 1；Thr45 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1 Asp59；The Glu15 of Ser15 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1；It is aobvious outside TRAC*01 The Ser54 of Arg53 and TRBC1*01 or the TRBC2*01 exons 1 of son 1；The Pro89 and TRBC1*01 of TRAC*01 exons 1 Or the Ala19 of TRBC2*01 exons 1；Or Tyr10 and TRBC1*01 or the TRBC2*01 exons 1 of TRAC*01 exons 1 Glu20.I.e. cysteine residues are instead of any group of site in above-mentioned α and β chain constant domain.It can be in TCR constant domain of the present invention One or more C-terminals truncate most 50 or 30 or 15 or 10 or 8 or more most most most most Few amino acid, so that it does not include cysteine residues to achieve the purpose that lack natural disulphide bonds, it can also be by that will be formed The cysteine residues of natural disulphide bonds sport another amino acid to reach above-mentioned purpose.
As described above, TCR of the invention may be embodied in artificial two sulphur introduced between the residue of itself α and β chain constant domain Key.It should be noted that the artificial disulfide bond with or without introducing described above between constant domain, TCR of the invention can contain TRAC Constant domain sequence and TRBC1 or TRBC2 constant domain sequence.The TRAC constant domain sequence and TRBC1 or TRBC2 constant domain sequence of TCR Column can be connected by the natural disulphide bonds being present in TCR.
To obtain sTCR, on the other hand, TCR of the present invention further includes the TCR to mutate in its hydrophobic core region, The mutation of these hydrophobic core regions is preferably capable making the stability-enhanced mutation of sTCR of the present invention, such as in publication number Described in patent document for WO2014/206304.Such TCR can mutate in its following hydrophobic core position of variable domain: (α and/or β chain) variable region amino acid the 11st, 13,19,21,53,76,89,91,94 and/or α chain J gene (TRAJ) are short Peptide ammino acid position the 3rd, 5,7 and/or β chain J gene (TRBJ) small peptide amino acid position reciprocal is 2nd, 4,6 reciprocal, The Position Number of middle amino acid sequence presses the Position Number listed in international immunogenetics information system (IMGT).This field Technical staff knows above-mentioned international immunogenetics information system, and the amino acid that different TCR can be obtained according to the database is residual Position Number of the base in IMGT.
The TCR that hydrophobic core region mutates in the present invention can be by α and the β chain of a flexible peptide chain link TCR can Variable domain and the solvable single-stranded TCR of stability constituted.It should be noted that flexible peptide chain can be any suitable connection TCR α in the present invention With the peptide chain of β chain variable domain.Single chain soluble TCR, α the chain variable domain amino acid sequence such as constructed in the embodiment of the present invention 4 It is classified as SEQ ID NO:32, the nucleotides sequence of coding is classified as SEQ ID NO:33；β chain variable domain amino acid sequence is SEQ ID NO:34, the nucleotides sequence of coding are classified as SEQ ID NO:35.
In addition, for stability, patent document 201510260322.4 also disclose α chain variable region in TCR with Introducing artificial interchain disulfide bond between β chain constant region can be such that the stability of TCR significantly improves.Therefore, height of the invention is affine Artificial interchain disulfide bond can also be contained between the α chain variable region and β chain constant region of power TCR.Specifically, in the α of the TCR The cysteine residues of artificial interchain disulfide bond are formed between chain variable region and β chain constant region instead of the 46th ammonia of TRAV 60th amino acids of base acid and TRBC1*01 or TRBC2*01 exons 1；The 47th amino acids and TRBC1*01 of TRAV or 61 amino acids of TRBC2*01 exons 1；The 46th amino acids of TRAV and TRBC1*01 or TRBC2*01 exons 1 61st amino acids；Or TRAV the 47th amino acids and TRBC1*01 or TRBC2*01 exons 1 the 60th amino acids. Preferably, such TCR may include all or part of TCR α chain of (I) in addition to its transmembrane domain, and (II) except its across All or part of TCR β chain other than spanning domain, wherein (I) and (II) includes the variable domain and at least part of TCR chain Constant domain, α chain and β chain form heterodimer.It is highly preferred that such TCR may include α chain variable domain and β chain variable domain And all or part of β chain constant domain in addition to transmembrane domain, but it does not contain α chain constant domain, the α chain of the TCR can Variable domain and β chain form heterodimer.
TCR of the invention can also be provided in the form of multivalence complex.Multivalent TCR complex of the invention include two, Three, four or more TCR of the present invention are combined and the polymer that is formed, can such as be generated with four dimerization domains of p53 The compound that the tetramer or multiple TCR of the present invention are formed in conjunction with another molecule.TCR compound of the invention can be used for body Outer or tracking in vivo or targeting present the cell of specific antigen, it can also be used to which generating has other multivalence TCR of such application multiple Close the intermediate of object.
TCR of the invention can be used alone, can also with conjugate with covalent or other modes in conjunction with, preferably with covalent Mode combines.The conjugate includes that detectable marker (for diagnostic purpose, presents wherein the TCR is used to detect The presence of the cell of FMNKFIYEI-HLA A0201 compound), therapeutic agent, PK (protein kinase) modified part or it is any more than The combination of these substances combines or coupling.
Detectable marker for diagnostic purposes includes but is not limited to: fluorescence or luminous marker, radioactive label Object, MRI (magnetic resonance imaging) or CT (x-ray tomography of electronic computer) contrast agent can generate detectable production The enzyme of object.
Can in conjunction with TCR of the present invention or coupling therapeutic agent include but is not limited to: 1. radionuclides (Koppe etc., 2005, (Cancer metastasis reviews) 24,539 is commented in metastasis of cancer)；2. biology poison (Chaudhary etc., 1989, Natural (Nature) 339,394；Epel etc., 2002, Cancer Immunol and immunization therapy (Cancer Immunology and Immunotherapy) 51,565)；3. cell factor such as IL-2 etc. (Gillies etc., 1992, National Academy of Sciences proceeding (PNAS) 89,1428；Card etc., 2004, Cancer Immunol and immunization therapy (Cancer Immunology and Immunotherapy) 53,345；Halin etc., 2003, cancer research (Cancer Research) 63,3202)；4. antibody Fc Segment (Mosquera etc., 2005, Journal of Immunology (The Journal Of Immunology) 174,4381)；5. antibody ScFv segment (Zhu etc., 1995, cancer International Periodicals (International Journal of Cancer) 62,319)；6. gold medal (Lapotko etc., 2005, cancer communicates (Cancer letters) 239,36 to nano particle/nanometer rods；Huang etc., 2006, beauty Chemical Society, state magazine (Journal of the American Chemical Society) 128,2115)；7. virion (Peng etc., 2004, gene therapy (Gene therapy) 11,1234)；8. liposome (Mamot etc., 2005, cancer research (Cancer research) 65,11631)；9. magnetic nanosphere；10. pro-drug activation enzymes (for example, DT- diaphorase (DTD) or Biphenyl base hydrolase-sample protein (BPHL))；11. chemotherapeutics (for example, cis-platinum) or any type of nano particle etc..
In addition, TCR of the invention can also be comprising derived from the heterozygosis TCR more than a kind of species sequence.For example, having Researches show that Muridae TCR can more effectively express in human T-cell than people TCR.Therefore, TCR of the present invention may include that people is variable The constant domain in domain and mouse.The defect of this method is possible to cause immune response.Therefore, adoptive T cell is used at it treat When should have regulation scheme to carry out immunosupress, to allow to express the implantation of the T cell of Muridae.
It should be understood that amino acid name herein is indicated using international single English alphabet or three English alphabets, amino The corresponding relationship of the single English alphabet and three English alphabets of sour title is as follows: Ala (A), Arg (R), Asn (N), Asp (D), Cys (C)、Gln(Q)、Glu(E)、Gly(G)、His(H)、Ile(I)、 Leu(L)、Lys(K)、Met(M)、Phe(F)、Pro(P)、 Ser(S)、Thr(T)、Trp(W)、 Tyr(Y)、Val(V)。
Nucleic acid molecules
The second aspect of the present invention provides the nucleic acid molecules of coding first aspect present invention TCR molecule or part thereof, institute Stating part can be one or more CDR, the variable domain and α chain and/or β chain of α and/or β chain.
The nucleotide sequence for encoding first aspect present invention TCR molecule alpha chain CDR region is as follows:
α CDR1-actagtataaacaat(SEQ ID NO:16)
α CDR2-atacgttcaaatgaaagagag(SEQ ID NO:17)
α CDR3-gctacggaccctcgaactggagccaatagtaagctgaca(SEQ ID NO:18)
The nucleotide sequence for encoding first aspect present invention TCR molecule β chain CDR region is as follows:
β CDR1-tctgaacacaaccgc(SEQ ID NO:19)
β CDR2-ttccagaatgaagctcaa(SEQ ID NO:20)
β CDR3-gccagcgagggactagcgtacgagcagtac(SEQ ID NO:21)
Therefore, encode the nucleic acid molecules of the present invention of TCR α chain of the present invention nucleotide sequence include SEQ ID NO:16, SEQ ID NO:17 and SEQ ID NO:18, and/or encode the nucleotide sequence of the nucleic acid molecules of the present invention of TCR β chain of the present invention Including SEQ ID NO:19, SEQ ID NO:20 and SEQ ID NO:21.
The nucleotide sequence of nucleic acid molecules of the present invention can be it is single-stranded or double-stranded, the nucleic acid molecules can be RNA or DNA, and may include or not include introne.Preferably, the nucleotide sequence of nucleic acid molecules of the present invention does not include introne But polypeptide of the present invention can be encoded, such as encodes the nucleotide sequence of the nucleic acid molecules of the present invention of TCR α chain variable domain of the present invention The nucleotide sequence of nucleic acid molecules of the present invention including SEQ ID NO:2 and/or coding TCR β chain variable domain of the present invention includes SEQ ID NO:6.Alternatively, the nucleotide sequence of the nucleic acid molecules of the present invention of coding TCR α chain variable domain of the present invention includes SEQ The nucleotide sequence of ID NO:33 and/or the nucleic acid molecules of the present invention of coding TCR β chain variable domain of the present invention includes SEQ ID NO:35.It is highly preferred that the nucleotide sequence of nucleic acid molecules of the present invention includes SEQ ID NO:4 and/or SEQ ID NO:8.Or Person, the nucleotides sequence of nucleic acid molecules of the present invention are classified as SEQ ID NO:31.
It should be understood that due to the degeneracy of genetic code, different nucleotide sequences can encode identical polypeptide.Therefore, it compiles The nucleic acid sequence that code book invents TCR can variant identical as present invention nucleic acid sequence shown in the drawings or degeneracy.With One of example in the present invention illustrates that " variant of degeneracy " refer to that coding has the albumen sequence of SEQ ID NO:1 Column, but the differentiated nucleic acid sequence of sequence with SEQ ID NO:2.
Nucleotide sequence can be through codon optimization.Different cells is above different in the utilization of specific codon , the codon in sequence can be changed to increase expression quantity according to the type of cell.Mammalian cell and it is a variety of its The codon usage table of allogene is well known to those skilled in the art.
Nucleic acid molecules full length sequence or its segment of the invention usually can with but be not limited to PCR amplification method, recombination method or Artificial synthesized method obtains.At present, it is already possible to obtain encoding TCR of the present invention (or its piece by chemical synthesis completely Section, or derivatives thereof) DNA sequence dna.Then the DNA sequence dna can be introduced various existing DNA moleculars as known in the art In (or such as carrier) and cell.DNA can be coding strand or noncoding strand.
Carrier
It, can in vivo or body the invention further relates to the carrier comprising nucleic acid molecules of the invention, including expression vector The construct of outer expression.Common carrier includes bacterial plasmid, bacteriophage and animals and plants virus.
Viral delivery systems include but is not limited to adenovirus vector, adeno-associated virus (AAV) carrier, herpesvirus vector, Retroviral vector, slow virus carrier, baculovirus vector.
Preferably, nucleotide of the invention can be transferred in cell by carrier, such as in T cell, so that the cell table Up to the TCR of AFP antigentic specificity.Ideally, which can should express to continual high levels in T cell.
Cell
The invention further relates to the genetically engineered host cell of carrier or coded sequence of the invention.The place Contain in carrier or chromosome of the invention in chief cell and is integrated with nucleic acid molecules of the invention.Host cell is selected from: protokaryon is thin Born of the same parents and eukaryocyte, such as Escherichia coli, yeast cells, Chinese hamster ovary celI etc..
In addition, the invention also includes the isolated cell for expressing TCR of the invention, especially T cell.The T cell can spread out It is born from the T cell separated from subject, or can be the mixed cellularity group separated from subject, such as periphery hemolymph A part of cell (PBL) group.Such as, which can be isolated from peripheral blood mononuclear cells (PBMC), can be CD4+Assist T Cell or CD8+Cytotoxic T cell.The cell can be in CD4+T helper cell/CD8+In the mixing group of cytotoxic T cell. Generally, which can be activated with antibody (e.g., the antibody of anti-CD3 or anti-CD28), to allow them to be easier to connect It is transfected, such as is transfected with the carrier of the nucleotide sequence comprising encoding TCR molecule of the present invention.
Alternatively, cell of the invention can also be or derived from stem cell, such as candidate stem cell (HSC).Gene is turned Moving to HSC not will lead in cell surface expression TCR, because stem cell surface does not express CD3 molecule.However, when stem cell point It turns to when migrating to the lymphoid precursor of thymus gland (lymphoid precursor), the expression of CD3 molecule will start in thymocyte The surface expression introducing TCR molecule.
It is suitable for carrying out T cell transfection (e.g., Robbins with the DNA or RNA that encode TCR of the present invention there are many method Equal, (2008) J.Immunol.180:6116-6131).The T cell for expressing TCR of the present invention can be used for adoptive immunotherapy. Those skilled in the art understand that many appropriate methods (e.g., the such as Rosenberg, (2008) Nat for carrying out adoptive treatment Rev Cancer8 (4): 299-308).
AFP antigen-related disease
The invention further relates to the method with AFP related disease is treated and/or prevented in subject comprising adoptive Shift the step of AFP specific T-cells are to the subject.The AFP specific T-cells can recognize FMNKFIYEI-HLA A0201 Compound.
The T cell of AFP specificity of the invention can be used for treating any presentation AFP antigen small peptide FMNKFIYEI-HLA The AFP related disease of A0201 compound.Including but not limited to tumour, such as hepatocellular carcinoma.
Treatment method
Can by separation with the patient of AFP antigen-related disease or the T cell of volunteer, and will be of the invention TCR is imported in above-mentioned T cell, is then fed back to the cell that these genetic engineerings are modified in patient body to treat.Cause This, the present invention provides a kind of method for treating AFP related disease, the T cell including the expression TCR of the present invention that will be separated is excellent Selection of land, the T cell derive from patient itself, are input in patient body.Generally, the T cell including (1) separation patient, (2) With nucleic acid molecules of the present invention or the nucleic acid molecules ex vivo transduction T cell of TCR molecule of the present invention can be encoded, (3) are by genetic engineering The T cell of modification is input in patient body.The quantity of separation, transfection and the cell fed back can be determined by doctor.
Main advantages of the present invention are:
(1) TCR of the invention can turn simultaneously in conjunction with AFP antigen small peptide compound FMNKFIYEI-HLA A0201 The cell for having led TCR of the present invention can have very strong lethal effect by specific activation and to target cell.
Following specific embodiment, the present invention is further explained.It should be understood that these embodiments are merely to illustrate the present invention Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip Part, such as (Sambrook and Russell et al., molecular cloning: laboratory manual (Molecular Cloning-A Laboratory Manual) (third edition) (2001) CSHL publishing house) described in condition, or according to proposed by manufacturer Condition.Unless otherwise stated, otherwise percentage and number are calculated by weight.Unless otherwise stated, otherwise percentage and number It calculates by weight.Experimental material used in following embodiment and reagent can obtain unless otherwise instructed from commercially available channel.
Embodiment 1 clones AFP antigen small peptide specific T-cells
Utilize synthesis small peptide FMNKFIYEI (SEQ ID NO.:9；Beijing SBS Genetech gene technology Co., Ltd) it stimulates and From in the peripheral blood lymphocytes (PBL) for the healthy volunteer that genotype is HLA-A0201.By FMNKFIYEI small peptide with have The HLA-A0201 renaturation of biotin labeling prepares pHLA monoploid.These monoploid and the Streptavidin (BD marked with PE Company) it is combined into the tetramer of PE label, sort the tetramer and anti-CD8-APC double positive cells.The cell of sorting is expanded, And secondary sorting is carried out according to the above method, then monoclonal is carried out with limiting dilution assay.Monoclonal cell tetramer staining, The double positive colonies screened are as shown in Figure 3.
The function and specificity of T cell clone are further detected by ELISPOT experiment.Those skilled in the art are ripe Know the method using ELISPOT experiment detection cell function.Effect used in the present embodiment IFN-γ ELISPOT experiment is thin Born of the same parents are the T cell clone obtained in the present invention, and target cell is the T2 cell for having loaded small peptide of the present invention, and control group is load The T2 cell of the T2 cell of other small peptides and unsupported any small peptide.
Prepare ELISPOT plate first, ELISPOT experimental procedure is as follows: in the following order adding each component of test Enter ELISPOT plate: 40 μ l T2 cells 5 × 105A cells/ml (i.e. 20,000 T2 cells/wells), 40 μ l effector cells After (2000 T cell clone/holes), 20 μ l specificity small peptides are added in experimental group, and 20 μ l non-specificity small peptides are added in control group, 20 μ l culture mediums (test medium) are added in blank group, and 2 multiple holes are arranged.Then be incubated overnight (37 DEG C, 5%CO2).Then Washing flat board simultaneously carries out secondary detection and colour developing, dry plate 1 hour, recycles immunodotting plate reader (ELISPOT READER system；AID company) count the spot formed on film.Experimental result is as shown in figure 14, and obtained specific antigen is special Specific T cell clone has specific reaction to the T2 cell for loading small peptide of the present invention, and to other unrelated peptides and unsupported small peptide T2 cell do not react substantially.
Embodiment 2 obtains the building of the tcr gene and carrier of AFP antigen small peptide specific T-cell clones
With the antigen small peptide screened in Quick-RNATMMiniPrep (ZYMO research) extracting embodiment 1 The total serum IgE of the restrictive T cell clone of FMNKFIYEI specificity, HLA-A0201.The synthesis of cDNA is using clontech's SMART RACE cDNA amplification kit, the primer of use are designed in the C-terminal conserved region of mankind's tcr gene.By sequence gram It is grand to being sequenced on carrier T (TAKARA).It should be noted that the sequence is complementary series, introne is not included.Through being sequenced, this pair The α chain and β chain-ordering structure difference of the TCR of positive colony expression is as depicted in figs. 1 and 2, Fig. 1 a, Fig. 1 b, Fig. 1 c, Fig. 1 d, figure 1e and Fig. 1 f is respectively TCR α chain variable domain amino acid sequence, TCR α chain variable domain nucleotide sequence, TCR α chain amino acid sequence Column, TCR α chain nucleotide sequence, the TCR α chain amino acid sequence with leader sequence and the TCR α chain core with leader sequence Nucleotide sequence；Fig. 2 a, Fig. 2 b, Fig. 2 c, Fig. 2 d, Fig. 2 e and Fig. 2 f are respectively that TCR β chain variable domain amino acid sequence, TCR β chain can Variable domain nucleotide sequence, TCR β chain amino acid sequence, TCR β chain nucleotide sequence, the TCR β chain amino acid with leader sequence Sequence and TCR β chain nucleotide sequence with leader sequence.
Identified, α chain includes the CDR with following amino acid sequence:
α CDR1-TSINN (SEQ ID NO:10)
α CDR2-IRSNERE (SEQ ID NO:11)
α CDR3-ATDPRTGANSKLT (SEQ ID NO:12)
β chain includes the CDR with following amino acid sequence:
β CDR1-SEHNR (SEQ ID NO:13)
β CDR2-FQNEAQ (SEQ ID NO:14)
β CDR3-ASEGLAYEQY (SEQ ID NO:15)
The full-length gene of TCR α chain and β chain is cloned into Lentiviral respectively by overlapping (overlap) PCR pLenti(addgene).Specifically: the full-length gene of TCR α chain and TCR β chain is attached to obtain with overlap PCR TCR α -2A-TCR β segment.It connects Lentiviral and TCR α -2A-TCR β digestion to obtain pLenti-TRA-2A- TRB-IRES-NGFR plasmid.It is used as control, while the also slow virus carrier pLenti-eGFP of building expression eGFP.Later Pseudovirus is packed with 293T/17 again.
Expression, refolding and the purifying of the solvable TCR of embodiment 3AFP antigen small peptide specificity
To obtain soluble TCR molecule, α the and β chain of TCR molecule of the invention can respectively only comprising its variable domain and Portion constant domain, and a cysteine residues are introduced in the constant domain of α and β chain respectively to form artificial two sulphur of interchain Key, the position for introducing cysteine residues is respectively Thr48 the and TRBC2*01 exons 1 of TRAC*01 exons 1 Ser57；The amino acid sequence of its α chain and nucleotide sequence respectively as shown in figures 4 a and 4b, the amino acid sequence of β chain with For nucleotide sequence respectively as shown in Fig. 5 a and Fig. 5 b, the cysteine residues of introducing with overstriking and underline alphabetical indicate.It is logical Cross " Molecular Cloning: A Laboratory room handbook " (Molecular Cloning a Laboratory Manual) (third edition, Sambrook and Russell) described in standard method by the objective gene sequence of above-mentioned TCR α and β chain after synthesizing respectively It is inserted into expression vector pET28a+ (Novagene), the cloning site of upstream and downstream is NcoI and NotI respectively.Insert Fragment warp It is errorless to cross sequencing confirmation.
The expression vector of TCR α and β chain is converted by chemical transformation respectively and enters expression bacterium BL21 (DE3), carefully Bacterium is grown with LB culture solution, in OD600It is induced when=0.6 with final concentration 0.5mM IPTG, is formed after α the and β chain expression of TCR Inclusion body is extracted by BugBuster Mix (Novagene), and through the repeated multiple times washing of BugBuster solution, packet Contain body and is finally dissolved in 6M guanidine hydrochloride, 10mM dithiothreitol (DTT) (DTT), 10mM ethylenediamine tetra-acetic acid (EDTA), 20mM Tris In (pH 8.1).
Dissolved TCR α and β chain are quickly mixed in 5M urea, 0.4M arginine, 20mM Tris with the mass ratio of 1:1 (pH 8.1), in 3.7mM cystamine, 6.6mM β-mercapoethylamine (4 DEG C), final concentration of 60mg/mL.It is mixed Solution is placed in dialysis (4 DEG C) in the deionized water of 10 times of volumes after conjunction, changes deionized water into buffer after 12 hours (20mM Tris, pH 8.0) continues at 4 DEG C and dialyses 12 hours.Solution after the completion of dialysis after 0.45 μM of membrane filtration, It is purified by anion-exchange column (HiTrap Q HP, 5ml, GE Healthcare).Eluting peak contain the successful α of renaturation and The TCR of β dimer is confirmed by SDS-PAGE glue.TCR then pass through gel permeation chromatography (HiPrep 16/60, Sephacryl S-100HR, GE Healthcare) it is further purified.TCR purity after purification is big by SDS-PAGE measurement In 90%, concentration is determined by BCA method.The SDS-PAGE glue figure for the sTCR that the present invention obtains is as shown in Figure 6.
The generation of the soluble single-chain T CR of embodiment 4AFP antigen small peptide specificity
According to patent document WO2014/206304, using the method for rite-directed mutagenesis by TCR α and β in embodiment 2 The variable domain of chain has been built into the stable soluble single-chain T CR molecule connected with flexible small peptide (linker).This is single-stranded Amino acid sequence and the nucleotide sequence difference of TCR molecule are as shown in figs. 7 a and 7b.The amino acid sequence of its α chain variable domain And nucleotide sequence difference is as figures 8 a and 8 b show；The amino acid sequence and nucleotide sequence of its β chain variable domain are respectively as schemed Shown in 9a and Fig. 9 b；Amino acid sequence and the nucleotide sequence difference of its linker sequence are as as-shown-in figures 10 a and 10b.
By target gene through I double digestion of Nco I and Not, it is connect with the pET28a carrier by Nco I and I double digestion of Not. Connection product is converted to E.coli DH5 α, is coated with the LB plate containing kanamycins, 37 DEG C of inversion overnight incubations, the picking positive gram Grand progress PCR screening, is sequenced positive recombinant, determines that sequence correctly extracts recombinant plasmid transformed to E.coli afterwards BL21 (DE3), for expressing.
Expression, renaturation and the purifying of the soluble single-chain T CR of embodiment 5AFP antigen small peptide specificity
BL21 (DE 3) bacterium colony containing recombinant plasmid pET28a- template strand prepared in embodiment 4 is all inoculated in In LB culture medium containing kanamycin, 37 DEG C culture to OD600 be 0.6-0.8, be added IPTG to final concentration of 0.5mM, 37 DEG C continue to cultivate 4h.5000rpm is centrifuged 15min and harvests cell precipitate, is split with Bugbuster Master Mix (Merck) Cell precipitate is solved, 6000rpm is centrifuged 15min and recycles inclusion body, then is washed with Bugbuster (Merck) to remove carefully Born of the same parents' fragment and membrane component, 6000 rpm are centrifuged 15min, collect inclusion body.By solubilization of inclusion bodies in buffer (20mM Tris- 8.0,8 M urea of HCl pH) in, high speed centrifugation removes insoluble matter, is dispensed after supernatant BCA standard measure, in -80 DEG C It saves backup.
In the single-stranded TCR inclusion body protein dissolved to 5mg, 2.5mL buffer (6M Gua-HCl, 50mM Tris- is added HCl pH 8.1,100mM NaCl, 10mM EDTA), add DTT to final concentration of 10mM, 37 DEG C of processing 30min.With note Emitter to 125mL renaturation buffer (100mM Tris-HCl pH 8.1,0.4M L-arginine, 5M urea, 2mM EDTA, 6.5mM β-mercapthoethylamine, 1.87mM Cystamine) in treated single-stranded TCR is added dropwise, 4 DEG C are stirred 10min to be mixed, renaturation solution is then packed into the cellulose membrane bag filter that interception is 4kDa, bag filter is placed in the water of 1L pre-cooling, 4 DEG C are slowly stirred overnight.After 17 hours, by dialyzate change into 1L pre-cooling buffer (20mM Tris-HCl pH 8.0), 4 DEG C continue the 8h that dialyses, then changes dialyzate into identical fresh buffer and continue dialysed overnight.After 17 hours, sample warp 0.45 μm of membrane filtration uses 20mM by anion-exchange column (HiTrap Q HP, GE Healthcare) after vacuum outgas The elution fraction of the 0-1M NaCl linear gradient elution liquid purifying protein that Tris-HCl pH 8.0 is prepared, collection carries out SDS- PAGE analysis further uses solvent resistant column (Superdex 75 10/300, GE after the component concentration comprising single-stranded TCR Healthcare it) is purified, target components also carry out SDS-PAGE analysis.
Elution fraction for BIAcore analysis further uses gel filtration to test its purity.Condition are as follows: chromatography Column Agilent Bio SEC-3 (7.8 × 300mm of 300A, φ), mobile phase are 150mM phosphate buffer, flow velocity 0.5mL/ Min, 25 DEG C of column temperature, ultraviolet detection wavelength 214nm.
The SDS-PAGE glue figure for the soluble single-chain T CR that the present invention obtains is as shown in figure 11.
Embodiment 6 combines characterization
BIAcore analysis
This example demonstrated soluble TCR molecules of the present invention can be special with FMNKFIYEI-HLA A0201 compound The opposite sex combines.
Using BIAcore T200 real-time analyzer detect TCR molecule obtained in embodiment 3 and embodiment 5 with The combination activity of FMNKFIYEI-HLA A0201 compound.Coupling is added in the antibody (GenScript) of anti-Streptavidin Antibody, is then flowed through the CM5 core activated in advance with EDC and NHS by buffer (10mM sodium-acetate buffer, pH 4.77) Piece makes antibody be fixed on chip surface, finally closes unreacted activating surface with the hydrochloric acid solution of ethanol amine, completes coupling Process, horizontal coupling is about 15,000 RU.
The Streptavidin of low concentration is set to flow through the chip surface of coated antibody, then by FMNKFIYEI-HLA A0201 compound flows through sense channel, and another channel is as reference channel, then by the biotin of 0.05 mM with 10 μ L/min's Flow velocity flows through chip 2min, closes the remaining binding site of Streptavidin.
The preparation process of above-mentioned FMNKFIYEI-HLA A0201 compound is as follows:
A. it purifies
The E.coli bacterium solution for collecting 100ml inducing expression heavy chain or light chain uses 10ml after 4 DEG C of 8000g are centrifuged 10min PBS washing thalline is primary, violent with 5ml BugBuster Master Mix Extraction Reagents (Merck) later Thallus is resuspended in concussion, and rotates in room temperature and be incubated for 20min, and later in 4 DEG C, 6000g is centrifuged 15min, discards supernatant, and collects packet Contain body.
Above-mentioned inclusion body is resuspended in 5ml BugBuster Master Mix, room temperature rotation is incubated for 5min；Add 30ml The BugBuster of 10 times of dilution is mixed, and 4 DEG C of 6000g are centrifuged 15min；It discards supernatant, 30ml is added to dilute 10 times Inclusion body is resuspended in BugBuster, mixes, and 4 DEG C of 6000g are centrifuged 15min, is repeated twice, adds 30ml 20mM Tris-HCl pH 8.0 are resuspended inclusion body, mix, and 4 DEG C of 6000g are centrifuged 15min, finally dissolve inclusion body with 20mM Tris-HCl 8M urea, SDS-PAGE detects inclusion body purity, and BCA kit surveys concentration.
B. renaturation
The small peptide FMNKFIYEI (Beijing SBS Genetech gene technology Co., Ltd) of synthesis is dissolved in DMSO to 20mg/ml Concentration.The inclusion body of light chain and heavy chain 8M urea, 20mM Tris pH 8.0,10mM DTT dissolve, and are added before renaturation 3M guanidine hydrochloride, 10mM sodium acetate, 10mM EDTA are further denaturalized.FMNKFIYEI peptide is added again with 25mg/L (final concentration) (0.4M L-arginine, 100 mM Tris pH 8.3,2mM EDTA, 0.5mM oxidative glutathione, 5mM are also for property buffer Prototype glutathione, 0.2mM PMSF, are cooled to 4 DEG C), then sequentially add the light chain of 20mg/L and the heavy chain of 90mg/L (final concentration, heavy chain are added in three times, 8h/ times), renaturation carry out at least 3 days at 4 DEG C to completion, and can SDS-PAGE detection answer Property success.
C. it is purified after renaturation
Make dialysis with the 20mM Tris pH 8.0 of 10 volumes to replace renaturation buffer, at least replaces buffer twice Sufficiently reduce the ionic strength of solution.With 0.45 μm of cellulose acetate sheets filtration protein solution after dialysis, then load Onto HiTrap Q HP (GE General Electric Co. Limited) anion-exchange column (5ml bed volume).Using Akta purifying instrument, (GE is general Electric corporation), the 0-400mM NaCl linear gradient liquid that 20mM Tris pH 8.0 is prepared elutes albumen, and pMHC is about in 250mM It is eluted at NaCl, collects all peak components, SDS-PAGE detects purity.
D. biotinylation
It with Mill ipore super filter tube by the pMHC molecular concentration of purifying, while being 20mM Tris pH by buffer exchange 8.0, biotinylation reagent 0.05M Bicine pH 8.3,10mM ATP, 10 mM MgOAc, 50 μM of D- is then added Biotin, 100 μ g/ml BirA enzymes (GST-BirA), incubation at room temperature mixture are stayed overnight, and whether SDS-PAGE detects biotinylation Completely.
E. the compound after purifying biological element
PMHC molecular concentration after being marked biotinylation with Mi llipore super filter tube is to 1ml, using Gel filtration The pMHC for analysing purifying biological element purifies instrument (GE General Electric Co. Limited) using Akta, is pre-equilibrated with filtered PBS HiPrepTM16/60S200HR column (GE General Electric Co. Limited), 1 ml of load concentrated biotinylation pMHC molecule, is then used PBS is with the elution of 1ml/min flow velocity.Biotinylated pMHC molecule occurs in about 55ml as unimodal elution.Merging contains egg The component of white matter is concentrated with Mill ipore super filter tube, and BCA method (Thermo) measures protein concentration, and protease is added and inhibits The packing of biotinylated pMHC molecule is stored in -80 DEG C by agent cocktail (Roche).
Using BIAcore Evaluation software computational dynamics parameter, obtain the TCR molecule of solubility of the invention with And the soluble single-chain T CR molecule that constructs of the present invention kinetic profile in conjunction with FMNKFIYEI-HLA A0201 compound point Not not as shown in Figure 12 and Figure 13.Map shows that the sTCR molecule and soluble single-chain T CR molecule that the present invention obtains are all It can be in conjunction with FMNKFIYEI-HLA A0201 compound.Meanwhile solubility of the invention also is had detected using the above method The combination of TCR molecule and other several irrelevant antigen small peptides and HLA compound is active, as the result is shown TCR molecule of the present invention and its His irrelevant antigen is without combination.
Embodiment 7 transduce TCR of the present invention T cell activation experiment
Building includes the slow virus carrier of TCR target gene of the present invention, and T cell of transduceing carries out ELISPOT functional verification Test.
ELISPOT scheme
Following tests is carried out to prove activating reaction of the T cell to target cell specificity of TCR transduction of the present invention.It utilizes Readout of the IFN-γ yield of ELISPOT testing inspection as t cell activation.
Reagent
Test medium: 10%FBS (Ji Bu can company (Gibco), catalog number (Cat.No.) 16000-044), 1640 (Ji Bu of RPMI Can company (Gibco), catalog number (Cat.No.) C11875500bt)
Washing buffer (PBST): 0.01M PBS/0.05% polysorbas20
PBS (Ji Bu can company (Gibco), catalog number (Cat.No.) C10010500BT)
96 orifice plate of PVDF ELISPOT (Merck Mi Libo (Merck Millipore), catalog number (Cat.No.) MSIPS4510)
People's IFN-γ ELISPOT PVDF- enzyme reagent kit (BD) (is captured and is detected equipped with required every other reagent Antibody, Streptavidin-alkaline phosphatase and BCIP/NBT solution)
Method
Target cell preparation
Target cell used in this experiment is the T2 cell for having loaded special small peptide.It is thin that target is prepared in assay medium Born of the same parents: target cell concentration is adjusted to 2.0 × 105A/milliliter, every hole take 100 microlitres to obtain 2.0 × 104A cells/well.
Effector cell's preparation
Effector cell's (T cell) of this experiment is the CD8 for expressing AFP antigen small peptide specificity TCR of the present invention+T cell, And with the CD8 of same volunteer's untransfected TCR of the present invention+T is as a control group.With AntiCD3 McAb/CD28 coating pearl (T cell amplification Object, life technologies) stimulation T cell, with carry AFP antigen small peptide specificity TCR gene lentiviruses transduction, The 1640 culture mediums amplification containing 10%FBS containing 50IU/ml IL-2 and 10ng/ml IL-7 is 9-12 days after transduction, so These cells are placed in test medium afterwards, 300g room temperature is centrifuged 10 minutes and is washed.Then by cell with 2 × it is required Final concentration is resuspended in test medium.Same processing negative control effector cell.
The preparation of small peptide solution
Corresponding small peptide is added in corresponding target cell (T2) experimental group, makes final concentration of 1 μ of the small peptide in ELISPOT orifice plate g/ml。
ELISPOT
According to the specification that manufacturer provides, prepare orifice plate as described below: with 10 milliliters of sterile PBS of every block of plate by 1:200 It dilutes anti-human IFN-γ and captures antibody, 100 microlitres of dilution is then captured into antibody etc. point, each hole is added.Orifice plate is incubated at 4 DEG C Overnight.After incubation, orifice plate is washed to remove extra capture antibody.The RPMI of 100 microlitres/Kong Hanyou 10%FBS is added 1640 culture mediums, and incubate orifice plate 2 hours at room temperature to close orifice plate.Then culture medium is washed away from orifice plate, by paper On flick and pat ELISPOT orifice plate to remove the washing buffer of any remnants.
Then all components of test are added by ELISPOT orifice plate using following sequence:
100 microlitres of target cell 2*105A cells/ml (obtains about 2*10 in total4A target cell/hole).
100 microlitres of effector cell (1*104A control effector cell/hole and AFP TCR positive T cell/hole).
All holes prepare addition in duplicate.
Then (37 DEG C/5%CO overnight of orifice plate are incubated2) second day, culture medium is abandoned, is washed orifice plate 2 times with distilled water, then It is washed 3 times, is patted on paper handkerchief to remove remaining washing buffer with washing buffer.Then with containing 10%FBS's Each hole is added by 100 microlitres/hole by 1:200 dilution detection antibody in PBS.It incubates orifice plate 2 hours at room temperature, then uses washing buffer Liquid washs 3 times, pats orifice plate on paper handkerchief to remove excessive washing buffer.
Streptavidin-alkaline phosphatase is diluted by 1:100 with the PBS containing 10%FBS, by 100 microlitres of diluted chains Mould Avidin-alkaline phosphatase is added each hole and incubates orifice plate 1 hour at room temperature.Then it is washed 4 times with washing buffer PBS is washed 2 times, pats orifice plate on paper handkerchief to remove excessive washing buffer and PBS.Kit is added after washing Develop in the 100 microlitres/hole of BCIP/NBT solution of offer.It is protected from light during development with masking foil covering orifice plate, stands 5-15 Minute.The spot of conventional detection development orifice plate during this period, determines the Best Times for terminating reaction.Remove BCIP/NBT solution And orifice plate is rinsed with distilled water to stop developing reaction, then orifice plate bottom is removed, it is straight to be dried at room temperature for orifice plate by drying It is completely dried to each hole, recycles immunodotting plate count meter (CTL, Celltech Ltd. (Cellular Technology Limited)) counterdie is formed in counting orifice spot.
As a result
The T cell (as described above) for examining TCR transduction of the present invention is tested to load AFP antigen small peptide by ELISPOT The IFN-γ release that the target cell of FMNKFIYEI reacts.It is drawn using graphpad prism6 and to be observed in each hole ELSPOT amount of speckle.
Experimental result is as shown in figure 15, and the T cell for the TCR of the present invention that transduces has the target cell for loading its special small peptide Good activating reaction, and the T cell for the TCR of the present invention that do not transduce to corresponding target cell substantially without activating reaction.
All references mentioned in the present invention is incorporated herein by reference, just as each document coverlet It is solely incorporated as with reference to such.In addition, it should also be understood that, after reading the above teachings of the present invention, those skilled in the art Member can make various changes or modifications the present invention, and such equivalent forms equally fall within the application the appended claims and limited Fixed range.
Sequence table
<110>Guangdong perfume (or spice) avenges accurate medical technology Co., Ltd
<120>T cell receptor of AFP antigen small peptide is identified
<130> P2017-1880
<160> 37
<170> PatentIn version 3.5
<210> 1
<211> 114
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 1
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Pro Arg Thr Gly
85 90 95
Ala Asn Ser Lys Leu Thr Phe Gly Lys Gly Ile Thr Leu Ser Val Arg
100 105 110
Pro Asp
<210> 2
<211> 342
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 2
agtcaacagg gagaagagga tcctcaggcc ttgagcatcc aggagggtga aaatgccacc 60
atgaactgca gttacaaaac tagtataaac aatttacagt ggtatagaca aaattcaggt 120
agaggccttg tccacctaat tttaatacgt tcaaatgaaa gagagaaaca cagtggaaga 180
ttaagagtca cgcttgacac ttccaagaaa agcagttcct tgttgatcac ggcttcccgg 240
gcagcagaca ctgcttctta cttctgtgct acggaccctc gaactggagc caatagtaag 300
ctgacatttg gaaaaggaat aactctgagt gttagaccag at 342
<210> 3
<211> 254
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 3
Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu Gly
1 5 10 15
Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn Leu
20 25 30
Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile Leu
35 40 45
Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val Thr
50 55 60
Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser Arg
65 70 75 80
Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Pro Arg Thr Gly
85 90 95
Ala Asn Ser Lys Leu Thr Phe Gly Lys Gly Ile Thr Leu Ser Val Arg
100 105 110
Pro Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp Ser
115 120 125
Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser Gln
130 135 140
Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp Lys
145 150 155 160
Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala Val
165 170 175
Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn Asn
180 185 190
Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser Cys
195 200 205
Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp Thr Asn Leu Asn
210 215 220
Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu Leu Leu Lys Val
225 230 235 240
Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser Ser
245 250
<210> 4
<211> 762
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 4
agtcaacagg gagaagagga tcctcaggcc ttgagcatcc aggagggtga aaatgccacc 60
atgaactgca gttacaaaac tagtataaac aatttacagt ggtatagaca aaattcaggt 120
agaggccttg tccacctaat tttaatacgt tcaaatgaaa gagagaaaca cagtggaaga 180
ttaagagtca cgcttgacac ttccaagaaa agcagttcct tgttgatcac ggcttcccgg 240
gcagcagaca ctgcttctta cttctgtgct acggaccctc gaactggagc caatagtaag 300
ctgacatttg gaaaaggaat aactctgagt gttagaccag atatccagaa ccctgaccct 360
gccgtgtacc agctgagaga ctctaaatcc agtgacaagt ctgtctgcct attcaccgat 420
tttgattctc aaacaaatgt gtcacaaagt aaggattctg atgtgtatat cacagacaaa 480
actgtgctag acatgaggtc tatggacttc aagagcaaca gtgctgtggc ctggagcaac 540
aaatctgact ttgcatgtgc aaacgccttc aacaacagca ttattccaga agacaccttc 600
ttccccagcc cagaaagttc ctgtgatgtc aagctggtcg agaaaagctt tgaaacagat 660
acgaacctaa actttcaaaa cctgtcagtg attgggttcc gaatcctcct cctgaaagtg 720
gccgggttta atctgctcat gacgctgcgg ctgtggtcca gc 762
<210> 5
<211> 112
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 5
Asp Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr Lys Arg Gly
1 5 10 15
Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu
20 25 30
Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg
50 55 60
Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln
65 70 75 80
Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Glu Gly
85 90 95
Leu Ala Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
100 105 110
<210> 6
<211> 336
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 6
gatactggag tctcccagga ccccagacac aagatcacaa agaggggaca gaatgtaact 60
ttcaggtgtg atccaatttc tgaacacaac cgcctttatt ggtaccgaca gaccctgggg 120
cagggcccag agtttctgac ttacttccag aatgaagctc aactagaaaa atcaaggctg 180
ctcagtgatc ggttctctgc agagaggcct aagggatctt tctccacctt ggagatccag 240
cgcacagagc agggggactc ggccatgtat ctctgtgcca gcgagggact agcgtacgag 300
cagtacttcg ggccgggcac caggctcacg gtcaca 336
<210> 7
<211> 291
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 7
Asp Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr Lys Arg Gly
1 5 10 15
Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu
20 25 30
Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg
50 55 60
Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln
65 70 75 80
Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Glu Gly
85 90 95
Leu Ala Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
100 105 110
Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu Pro
115 120 125
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys Leu
130 135 140
Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val Asn
145 150 155 160
Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln Pro Leu Lys
165 170 175
Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser Ser Arg Leu
180 185 190
Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His Phe Arg Cys
195 200 205
Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln Asp
210 215 220
Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly Arg
225 230 235 240
Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly Val Leu Ser
245 250 255
Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala
260 265 270
Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys Arg Lys Asp
275 280 285
Ser Arg Gly
290
<210> 8
<211> 873
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 8
gatactggag tctcccagga ccccagacac aagatcacaa agaggggaca gaatgtaact 60
ttcaggtgtg atccaatttc tgaacacaac cgcctttatt ggtaccgaca gaccctgggg 120
cagggcccag agtttctgac ttacttccag aatgaagctc aactagaaaa atcaaggctg 180
ctcagtgatc ggttctctgc agagaggcct aagggatctt tctccacctt ggagatccag 240
cgcacagagc agggggactc ggccatgtat ctctgtgcca gcgagggact agcgtacgag 300
cagtacttcg ggccgggcac caggctcacg gtcacagagg acctgaaaaa cgtgttccca 360
cccgaggtcg ctgtgtttga gccatcagaa gcagagatct cccacaccca aaaggccaca 420
ctggtgtgcc tggccacagg cttctacccc gaccacgtgg agctgagctg gtgggtgaat 480
gggaaggagg tgcacagtgg ggtcagcaca gacccgcagc ccctcaagga gcagcccgcc 540
ctcaatgact ccagatactg cctgagcagc cgcctgaggg tctcggccac cttctggcag 600
aacccccgca accacttccg ctgtcaagtc cagttctacg ggctctcgga gaatgacgag 660
tggacccagg atagggccaa acctgtcacc cagatcgtca gcgccgaggc ctggggtaga 720
gcagactgtg gcttcacctc cgagtcttac cagcaagggg tcctgtctgc caccatcctc 780
tatgagatct tgctagggaa ggccaccttg tatgccgtgc tggtcagtgc cctcgtgctg 840
atggccatgg tcaagagaaa ggattccaga ggc 873
<210> 9
<211> 9
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 9
Phe Met Asn Lys Phe Ile Tyr Glu Ile
1 5
<210> 10
<211> 5
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 10
Thr Ser Ile Asn Asn
1 5
<210> 11
<211> 7
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 11
Ile Arg Ser Asn Glu Arg Glu
1 5
<210> 12
<211> 13
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 12
Ala Thr Asp Pro Arg Thr Gly Ala Asn Ser Lys Leu Thr
1 5 10
<210> 13
<211> 5
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 13
Ser Glu His Asn Arg
1 5
<210> 14
<211> 6
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 14
Phe Gln Asn Glu Ala Gln
1 5
<210> 15
<211> 10
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 15
Ala Ser Glu Gly Leu Ala Tyr Glu Gln Tyr
1 5 10
<210> 16
<211> 15
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 16
actagtataa acaat 15
<210> 17
<211> 21
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 17
atacgttcaa atgaaagaga g 21
<210> 18
<211> 39
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 18
gctacggacc ctcgaactgg agccaatagt aagctgaca 39
<210> 19
<211> 15
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 19
tctgaacaca accgc 15
<210> 20
<211> 18
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 20
ttccagaatg aagctcaa 18
<210> 21
<211> 30
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 21
gccagcgagg gactagcgta cgagcagtac 30
<210> 22
<211> 274
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 22
Met Glu Thr Leu Leu Gly Val Ser Leu Val Ile Leu Trp Leu Gln Leu
1 5 10 15
Ala Arg Val Asn Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser
20 25 30
Ile Gln Glu Gly Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser
35 40 45
Ile Asn Asn Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val
50 55 60
His Leu Ile Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg
65 70 75 80
Leu Arg Val Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile
85 90 95
Thr Ala Ser Arg Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp
100 105 110
Pro Arg Thr Gly Ala Asn Ser Lys Leu Thr Phe Gly Lys Gly Ile Thr
115 120 125
Leu Ser Val Arg Pro Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln
130 135 140
Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp
145 150 155 160
Phe Asp Ser Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr
165 170 175
Ile Thr Asp Lys Thr Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser
180 185 190
Asn Ser Ala Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn
195 200 205
Ala Phe Asn Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro
210 215 220
Glu Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu Thr Asp
225 230 235 240
Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg Ile Leu
245 250 255
Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr Leu Arg Leu Trp
260 265 270
Ser Ser
<210> 23
<211> 822
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 23
atggaaactc tcctgggagt gtctttggtg attctatggc ttcaactggc tagggtgaac 60
agtcaacagg gagaagagga tcctcaggcc ttgagcatcc aggagggtga aaatgccacc 120
atgaactgca gttacaaaac tagtataaac aatttacagt ggtatagaca aaattcaggt 180
agaggccttg tccacctaat tttaatacgt tcaaatgaaa gagagaaaca cagtggaaga 240
ttaagagtca cgcttgacac ttccaagaaa agcagttcct tgttgatcac ggcttcccgg 300
gcagcagaca ctgcttctta cttctgtgct acggaccctc gaactggagc caatagtaag 360
ctgacatttg gaaaaggaat aactctgagt gttagaccag atatccagaa ccctgaccct 420
gccgtgtacc agctgagaga ctctaaatcc agtgacaagt ctgtctgcct attcaccgat 480
tttgattctc aaacaaatgt gtcacaaagt aaggattctg atgtgtatat cacagacaaa 540
actgtgctag acatgaggtc tatggacttc aagagcaaca gtgctgtggc ctggagcaac 600
aaatctgact ttgcatgtgc aaacgccttc aacaacagca ttattccaga agacaccttc 660
ttccccagcc cagaaagttc ctgtgatgtc aagctggtcg agaaaagctt tgaaacagat 720
acgaacctaa actttcaaaa cctgtcagtg attgggttcc gaatcctcct cctgaaagtg 780
gccgggttta atctgctcat gacgctgcgg ctgtggtcca gc 822
<210> 24
<211> 310
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 24
Met Gly Thr Ser Leu Leu Cys Trp Met Ala Leu Cys Leu Leu Gly Ala
1 5 10 15
Asp His Ala Asp Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr
20 25 30
Lys Arg Gly Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His
35 40 45
Asn Arg Leu Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe
50 55 60
Leu Thr Tyr Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu
65 70 75 80
Ser Asp Arg Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu
85 90 95
Glu Ile Gln Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala
100 105 110
Ser Glu Gly Leu Ala Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu
115 120 125
Thr Val Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val
130 135 140
Phe Glu Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu
145 150 155 160
Val Cys Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp
165 170 175
Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro Gln
180 185 190
Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Cys Leu Ser
195 200 205
Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln Asn Pro Arg Asn His
210 215 220
Phe Arg Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp
225 230 235 240
Thr Gln Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala
245 250 255
Trp Gly Arg Ala Asp Cys Gly Phe Thr Ser Glu Ser Tyr Gln Gln Gly
260 265 270
Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala Thr
275 280 285
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val Lys
290 295 300
Arg Lys Asp Ser Arg Gly
305 310
<210> 25
<211> 930
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 25
atgggcacca gcctcctctg ctggatggcc ctgtgtctcc tgggggcaga tcacgcagat 60
actggagtct cccaggaccc cagacacaag atcacaaaga ggggacagaa tgtaactttc 120
aggtgtgatc caatttctga acacaaccgc ctttattggt accgacagac cctggggcag 180
ggcccagagt ttctgactta cttccagaat gaagctcaac tagaaaaatc aaggctgctc 240
agtgatcggt tctctgcaga gaggcctaag ggatctttct ccaccttgga gatccagcgc 300
acagagcagg gggactcggc catgtatctc tgtgccagcg agggactagc gtacgagcag 360
tacttcgggc cgggcaccag gctcacggtc acagaggacc tgaaaaacgt gttcccaccc 420
gaggtcgctg tgtttgagcc atcagaagca gagatctccc acacccaaaa ggccacactg 480
gtgtgcctgg ccacaggctt ctaccccgac cacgtggagc tgagctggtg ggtgaatggg 540
aaggaggtgc acagtggggt cagcacagac ccgcagcccc tcaaggagca gcccgccctc 600
aatgactcca gatactgcct gagcagccgc ctgagggtct cggccacctt ctggcagaac 660
ccccgcaacc acttccgctg tcaagtccag ttctacgggc tctcggagaa tgacgagtgg 720
acccaggata gggccaaacc tgtcacccag atcgtcagcg ccgaggcctg gggtagagca 780
gactgtggct tcacctccga gtcttaccag caaggggtcc tgtctgccac catcctctat 840
gagatcttgc tagggaaggc caccttgtat gccgtgctgg tcagtgccct cgtgctgatg 900
gccatggtca agagaaagga ttccagaggc 930
<210> 26
<211> 208
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 26
Met Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu
1 5 10 15
Gly Glu Asn Ala Thr Met Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn
20 25 30
Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile
35 40 45
Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val
50 55 60
Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Leu Ile Thr Ala Ser
65 70 75 80
Arg Ala Ala Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Pro Arg Thr
85 90 95
Gly Ala Asn Ser Lys Leu Thr Phe Gly Lys Gly Ile Thr Leu Ser Val
100 105 110
Arg Pro Asp Ile Gln Asn Pro Asp Pro Ala Val Tyr Gln Leu Arg Asp
115 120 125
Ser Lys Ser Ser Asp Lys Ser Val Cys Leu Phe Thr Asp Phe Asp Ser
130 135 140
Gln Thr Asn Val Ser Gln Ser Lys Asp Ser Asp Val Tyr Ile Thr Asp
145 150 155 160
Lys Cys Val Leu Asp Met Arg Ser Met Asp Phe Lys Ser Asn Ser Ala
165 170 175
Val Ala Trp Ser Asn Lys Ser Asp Phe Ala Cys Ala Asn Ala Phe Asn
180 185 190
Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro Ser Pro Glu Ser Ser
195 200 205
<210> 27
<211> 624
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 27
atgagccagc agggcgaaga agatcctcag gccttgagca tccaggaggg tgaaaatgcc 60
accatgaact gcagttacaa aactagtata aacaatttac agtggtatag acaaaattca 120
ggtagaggcc ttgtccacct aattttaata cgttcaaatg aaagagagaa acacagtgga 180
agattaagag tcacgcttga cacttccaag aaaagcagtt ccttgttgat cacggcttcc 240
cgggcagcag acactgcttc ttacttctgt gctacggacc ctcgaactgg agccaatagt 300
aagctgacat ttggaaaagg aataactctg agtgttagac cagatatcca gaaccctgac 360
cctgccgtgt accagctgag agactctaag tcgagtgaca agtctgtctg cctattcacc 420
gattttgatt ctcaaacaaa tgtgtcacaa agtaaggatt ctgatgtgta tatcacagac 480
aaatgtgtgc tagacatgag gtctatggac ttcaagagca acagtgctgt ggcctggagc 540
aacaaatctg actttgcatg tgcaaacgcc ttcaacaaca gcattattcc agaagacacc 600
ttcttcccca gcccagaaag ttcc 624
<210> 28
<211> 243
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 28
Met Asp Thr Gly Val Ser Gln Asp Pro Arg His Lys Ile Thr Lys Arg
1 5 10 15
Gly Gln Asn Val Thr Phe Arg Cys Asp Pro Ile Ser Glu His Asn Arg
20 25 30
Leu Tyr Trp Tyr Arg Gln Thr Leu Gly Gln Gly Pro Glu Phe Leu Thr
35 40 45
Tyr Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp
50 55 60
Arg Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile
65 70 75 80
Gln Arg Thr Glu Gln Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Glu
85 90 95
Gly Leu Ala Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val
100 105 110
Thr Glu Asp Leu Lys Asn Val Phe Pro Pro Glu Val Ala Val Phe Glu
115 120 125
Pro Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr Leu Val Cys
130 135 140
Leu Ala Thr Gly Phe Tyr Pro Asp His Val Glu Leu Ser Trp Trp Val
145 150 155 160
Asn Gly Lys Glu Val His Ser Gly Val Cys Thr Asp Pro Gln Pro Leu
165 170 175
Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr Ala Leu Ser Ser Arg
180 185 190
Leu Arg Val Ser Ala Thr Phe Trp Gln Asp Pro Arg Asn His Phe Arg
195 200 205
Cys Gln Val Gln Phe Tyr Gly Leu Ser Glu Asn Asp Glu Trp Thr Gln
210 215 220
Asp Arg Ala Lys Pro Val Thr Gln Ile Val Ser Ala Glu Ala Trp Gly
225 230 235 240
Arg Ala Asp
<210> 29
<211> 729
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 29
atggataccg gcgtgagcca ggaccccaga cacaagatca caaagagggg acagaatgta 60
actttcaggt gtgatccaat ttctgaacac aaccgccttt attggtaccg acagaccctg 120
gggcagggcc cagagtttct gacttacttc cagaatgaag ctcaactaga aaaatcaagg 180
ctgctcagtg atcggttctc tgcagagagg cctaagggat ctttctccac cttggagatc 240
cagcgcacag agcaggggga ctcggccatg tatctctgtg ccagcgaggg actagcgtac 300
gagcagtact tcgggccggg caccaggctc acggtcacag aggacctgaa aaacgtgttc 360
ccacccgagg tcgctgtgtt tgagccatca gaagcagaga tctcccacac ccaaaaggcc 420
acactggtgt gcctggccac cggtttctac cccgaccacg tggagctgag ctggtgggtg 480
aatgggaagg aggtgcacag tggggtctgc acagacccgc agcccctcaa ggagcagccc 540
gccctcaatg actccagata cgctctgagc agccgcctga gggtctcggc caccttctgg 600
caggaccccc gcaaccactt ccgctgtcaa gtccagttct acgggctctc ggagaatgac 660
gagtggaccc aggatagggc caaacccgtc acccagatcg tcagcgccga ggcctggggt 720
agagcagac 729
<210> 30
<211> 250
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 30
Ala Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu
1 5 10 15
Gly Glu Asn Val Thr Ile Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn
20 25 30
Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile
35 40 45
Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val
50 55 60
Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Glu Ile Thr Asp Val
65 70 75 80
Arg Pro Ser Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Pro Arg Thr
85 90 95
Gly Ala Asn Ser Lys Leu Thr Phe Gly Lys Gly Ile Thr Leu Ser Val
100 105 110
Arg Pro Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser
115 120 125
Glu Gly Gly Gly Ser Glu Gly Gly Thr Gly Asp Thr Gly Val Ser Gln
130 135 140
Asp Pro Arg His Leu Ser Val Lys Arg Gly Gln Asn Val Thr Leu Arg
145 150 155 160
Cys Asp Pro Ile Ser Glu His Asn Arg Leu Tyr Trp Tyr Arg Gln Thr
165 170 175
Pro Gly Gln Gly Pro Glu Phe Leu Thr Tyr Phe Gln Asn Glu Ala Gln
180 185 190
Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg Phe Ser Ala Glu Arg Pro
195 200 205
Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln Arg Val Glu Pro Gly Asp
210 215 220
Ser Ala Met Tyr Leu Cys Ala Ser Glu Gly Leu Ala Tyr Glu Gln Tyr
225 230 235 240
Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
245 250
<210> 31
<211> 750
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 31
ggttctcaac aaggtgaaga agacccgcag gcgctgagca tccaagaggg cgaaaacgtg 60
accattaact gcagctacaa gaccagcatc aacaacctgc agtggtatcg tcaaaacagc 120
ggtcgtggcc tggttcacct gatcctgatt cgtagcaacg agcgtgaaaa acacagcggt 180
cgtctgcgtg tgaccctgga caccagcaag aaaagcagca gcctggagat taccgacgtt 240
cgtccgagcg ataccgcgag ctatttttgc gcgaccgatc cgcgtaccgg tgcgaacagc 300
aagctgacct ttggtaaagg tattaccctg agcgtgcgtc cgggtggcgg tagcgagggc 360
ggtggcagcg aaggtggcgg tagcgagggc ggtggcagcg aaggtggcac cggtgacacc 420
ggcgttagcc aggatccgcg tcacctgagc gtgaagcgtg gtcaaaacgt taccctgcgt 480
tgcgatccga ttagcgagca caaccgtctg tactggtatc gtcagacccc gggtcaaggc 540
ccggaattcc tgacctactt tcagaacgag gcgcaactgg aaaagagccg tctgctgagc 600
gaccgtttca gcgcggaacg tccgaaaggt agctttagca ccctggagat ccagcgtgtg 660
gaaccgggtg atagcgcgat gtatctgtgc gcgagcgagg gcctggcgta cgaacaatat 720
ttcggtccgg gcacccgtct gaccgttacc 750
<210> 32
<211> 114
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 32
Ala Ser Gln Gln Gly Glu Glu Asp Pro Gln Ala Leu Ser Ile Gln Glu
1 5 10 15
Gly Glu Asn Val Thr Ile Asn Cys Ser Tyr Lys Thr Ser Ile Asn Asn
20 25 30
Leu Gln Trp Tyr Arg Gln Asn Ser Gly Arg Gly Leu Val His Leu Ile
35 40 45
Leu Ile Arg Ser Asn Glu Arg Glu Lys His Ser Gly Arg Leu Arg Val
50 55 60
Thr Leu Asp Thr Ser Lys Lys Ser Ser Ser Leu Glu Ile Thr Asp Val
65 70 75 80
Arg Pro Ser Asp Thr Ala Ser Tyr Phe Cys Ala Thr Asp Pro Arg Thr
85 90 95
Gly Ala Asn Ser Lys Leu Thr Phe Gly Lys Gly Ile Thr Leu Ser Val
100 105 110
Arg Pro
<210> 33
<211> 342
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 33
ggttctcaac aaggtgaaga agacccgcag gcgctgagca tccaagaggg cgaaaacgtg 60
accattaact gcagctacaa gaccagcatc aacaacctgc agtggtatcg tcaaaacagc 120
ggtcgtggcc tggttcacct gatcctgatt cgtagcaacg agcgtgaaaa acacagcggt 180
cgtctgcgtg tgaccctgga caccagcaag aaaagcagca gcctggagat taccgacgtt 240
cgtccgagcg ataccgcgag ctatttttgc gcgaccgatc cgcgtaccgg tgcgaacagc 300
aagctgacct ttggtaaagg tattaccctg agcgtgcgtc cg 342
<210> 34
<211> 112
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 34
Asp Thr Gly Val Ser Gln Asp Pro Arg His Leu Ser Val Lys Arg Gly
1 5 10 15
Gln Asn Val Thr Leu Arg Cys Asp Pro Ile Ser Glu His Asn Arg Leu
20 25 30
Tyr Trp Tyr Arg Gln Thr Pro Gly Gln Gly Pro Glu Phe Leu Thr Tyr
35 40 45
Phe Gln Asn Glu Ala Gln Leu Glu Lys Ser Arg Leu Leu Ser Asp Arg
50 55 60
Phe Ser Ala Glu Arg Pro Lys Gly Ser Phe Ser Thr Leu Glu Ile Gln
65 70 75 80
Arg Val Glu Pro Gly Asp Ser Ala Met Tyr Leu Cys Ala Ser Glu Gly
85 90 95
Leu Ala Tyr Glu Gln Tyr Phe Gly Pro Gly Thr Arg Leu Thr Val Thr
100 105 110
<210> 35
<211> 336
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 35
gacaccggcg ttagccagga tccgcgtcac ctgagcgtga agcgtggtca aaacgttacc 60
ctgcgttgcg atccgattag cgagcacaac cgtctgtact ggtatcgtca gaccccgggt 120
caaggcccgg aattcctgac ctactttcag aacgaggcgc aactggaaaa gagccgtctg 180
ctgagcgacc gtttcagcgc ggaacgtccg aaaggtagct ttagcaccct ggagatccag 240
cgtgtggaac cgggtgatag cgcgatgtat ctgtgcgcga gcgagggcct ggcgtacgaa 300
caatatttcg gtccgggcac ccgtctgacc gttacc 336
<210> 36
<211> 24
<212> PRT
<213>artificial sequence (Artificial sequence)
<400> 36
Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly Gly Gly Ser Glu Gly
1 5 10 15
Gly Gly Ser Glu Gly Gly Thr Gly
20
<210> 37
<211> 72
<212> DNA
<213>artificial sequence (Artificial sequence)
<400> 37
ggtggcggta gcgagggcgg tggcagcgaa ggtggcggta gcgagggcgg tggcagcgaa 60
ggtggcaccg gt 72

Claims (10)

1. a kind of T cell receptor (TCR), which is characterized in that the TCR can be with FMNKFIYEI-HLA A0201 compound knot It closes；Preferably, the TCR includes TCR α chain variable domain and TCR β chain variable domain, which is characterized in that the TCR α chain variable domain CDR3 amino acid sequence be ATDPRTGANSKLT (SEQ ID NO:12)；And/or the CDR3 of the TCR β chain variable domain Amino acid sequence is ASEGLAYEQY (SEQ ID NO:15)；
It is highly preferred that 3 complementary determining regions (CDR) of the TCR α chain variable domain are as follows:
αCDR1-TSINN(SEQ ID NO:10)
αCDR2-IRSNERE(SEQ ID NO:11)
αCDR3-ATDPRTGANSKLT(SEQ ID NO:12)；And/or
3 complementary determining regions of the TCR β chain variable domain are as follows:
βCDR1-SEHNR(SEQ ID NO:13)
βCDR2-FQNEAQ(SEQ ID NO:14)
βCDR3-ASEGLAYEQY(SEQ ID NO:15)。
2. TCR as described in claim 1, which is characterized in that described it includes TCR α chain variable domain and TCR β chain variable domain TCR α chain variable domain is the amino acid sequence for having at least 90% sequence identity with SEQ ID NO:1；And/or the TCR β chain Variable domain is the amino acid sequence for having at least 90% sequence identity with SEQ ID NO:5.
3. TCR as described in claim 1, which is characterized in that the α chain of the TCR and/or the end C- or N- of β chain are combined with Conjugate；Preferably, the conjugate in conjunction with the T cell receptor is detectable marker, therapeutic agent, PK modified part or appoints The combination of what these substance；Preferably, the therapeutic agent is anti-CD 3 antibodies.
4. a kind of multivalent TCR complex, which is characterized in that contain at least two TCR molecule, and at least one TCR therein Molecule is TCR described in any one of the claims.
5. a kind of nucleic acid molecules, which is characterized in that the nucleic acid molecules include to encode TCR described in any of the above-described claim points The nucleic acid sequence or its complementary series of son；
Preferably, the nucleic acid molecules include nucleotide sequence SEQ ID NO:2 or the SEQ ID of coding TCR α chain variable domain NO:33；And/or
The nucleic acid molecules include the nucleotide sequence SEQ ID NO:6 or SEQ ID NO:35 of coding TCR β chain variable domain.
6. a kind of carrier, which is characterized in that the carrier contains nucleic acid molecules described in claim 5；Preferably, described Carrier is viral vectors；It is highly preferred that the carrier is slow virus carrier.
7. a kind of isolated host cell, which is characterized in that contain the carrier described in claim 6 in the host cell Or nucleic acid molecules described in the claim 5 of external source are integrated in chromosome.
8. a kind of cell, which is characterized in that institute in nucleic acid molecules described in the cell transduction claim 5 or claim 6 State carrier；Preferably, the cell is T cell or stem cell.
9. a kind of pharmaceutical composition, which is characterized in that the composition contains pharmaceutically acceptable carrier and claim TCR described in any one of 1-3, TCR compound described in claim 4, nucleic acid molecules described in claim 5 or power Benefit requires cell described in 8.
10. TCR compound or right described in T cell receptor of any of claims 1-3 or claim 4 It is required that the purposes of cell described in 8, which is characterized in that be used to prepare the drug for the treatment of tumour or autoimmune disease.
CN201710900629.5A 2017-09-28 2017-09-28 T cell receptor recognizing AFP antigen short peptides Active CN109575121B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710900629.5A CN109575121B (en) 2017-09-28 2017-09-28 T cell receptor recognizing AFP antigen short peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710900629.5A CN109575121B (en) 2017-09-28 2017-09-28 T cell receptor recognizing AFP antigen short peptides

Publications (2)

Publication Number Publication Date
CN109575121A true CN109575121A (en) 2019-04-05
CN109575121B CN109575121B (en) 2022-09-09

Family

ID=65914031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710900629.5A Active CN109575121B (en) 2017-09-28 2017-09-28 T cell receptor recognizing AFP antigen short peptides

Country Status (1)

Country Link
CN (1) CN109575121B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390875A (en) * 2019-08-16 2021-02-23 广东香雪精准医疗技术有限公司 High-affinity T cell receptor for identifying AFP
WO2021035446A1 (en) * 2019-08-23 2021-03-04 广东香雪精准医疗技术有限公司 T cell receptor for recognizing afp antigen short peptide and encoding sequence thereof
WO2021139699A1 (en) * 2020-01-06 2021-07-15 香雪生命科学技术（广东）有限公司 T cell receptor for recognizing afp and coding sequence thereof
WO2021170116A1 (en) * 2020-02-28 2021-09-02 香雪生命科学技术（广东）有限公司 T cell receptor recognizing afp

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104087592A (en) * 2014-05-13 2014-10-08 天津医科大学总医院 AFP[158-166] specific TCR gene, its transgenic T cell, and in-vitro proliferation method and use of transgenic T cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104087592A (en) * 2014-05-13 2014-10-08 天津医科大学总医院 AFP[158-166] specific TCR gene, its transgenic T cell, and in-vitro proliferation method and use of transgenic T cell

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390875A (en) * 2019-08-16 2021-02-23 广东香雪精准医疗技术有限公司 High-affinity T cell receptor for identifying AFP
WO2021032020A1 (en) * 2019-08-16 2021-02-25 广东香雪精准医疗技术有限公司 High-affinity t-cell receptor for recognizing afp
CN112390875B (en) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 High-affinity T cell receptor for identifying AFP
WO2021035446A1 (en) * 2019-08-23 2021-03-04 广东香雪精准医疗技术有限公司 T cell receptor for recognizing afp antigen short peptide and encoding sequence thereof
WO2021139699A1 (en) * 2020-01-06 2021-07-15 香雪生命科学技术（广东）有限公司 T cell receptor for recognizing afp and coding sequence thereof
WO2021170116A1 (en) * 2020-02-28 2021-09-02 香雪生命科学技术（广东）有限公司 T cell receptor recognizing afp

Also Published As

Publication number Publication date
CN109575121B (en) 2022-09-09

Similar Documents

Publication Publication Date Title
CN106478809B (en) Identify the TCR of PRAME antigen small peptide
CN106519019B (en) Identify the TCR of PRAME antigen
CN107197625A (en) Recognize the φt cell receptor of the antigen small peptides of NY ESO 1
CN106632660A (en) T cell receptor (TCR) capable of identifying NY-ESO-1 antigen short-peptides
CN106699874B (en) Identify the T cell receptor of PRAME antigen small peptide
CN106749620A (en) Recognize the φt cell receptor of MAGE A1 antigen small peptides
CN106478808B (en) Identify the T cell receptor of NY-ESO-1 antigen small peptides
CN110343166A (en) Identify the T cell receptor of AFP antigen small peptide
CN110343167A (en) Identify the T cell receptor of SSX2 antigen small peptide
CN110776562B (en) T cell receptor for identifying AFP antigen
CN110577591B (en) T cell receptor for identifying AFP antigen short peptide and its coding sequence
CN106831978A (en) Recognize the φt cell receptor of DAGE
CN109575121A (en) Identify the T cell receptor of AFP antigen small peptide
CN106478807A (en) The T cell receptor of identification MAGE-A3
CN106084036A (en) Identify the φt cell receptor of DAGE small peptide
CN106336457B (en) Identify the φt cell receptor of MAGE A3 antigen small peptides
CN110272482A (en) Identify the T cell receptor of PRAME antigen small peptide
CN106459179B (en) Identify the T cell receptor of RHAMM antigen small peptides
CN106632658A (en) TCR (T Cell Receptor) for identifying NY-ESO (New York-Esophageal Squamous Cell Carcinomas)-1 antigen short peptide
CN108264550A (en) It is a kind of to identify the TCR from PRAME antigen small peptide
CN109251244A (en) A kind of identification is derived from the TCR of EBV memebrane protein LMP1 antigen
CN109251243A (en) A kind of T cell receptor identifying SAGE1 antigen and the nucleic acid for encoding this receptor
CN107987156A (en) Identify the TCR of SAGE1 antigen small peptides
CN109575120A (en) Identify the TCR and its coded sequence of PRAME antigen small peptide
CN110407927A (en) A kind of TCR identifying AFP antigen

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210422

Address after: 519031 2715 office building, no.3000 Huandao East Road, Hengqin New District, Zhuhai City, Guangdong Province

Applicant after: Xiangxue Life Science Technology (Guangdong) Co.,Ltd.

Address before: 510663 Jin Feng Park Road, Guangzhou, Guangdong high tech Industrial Development Zone, Guangzhou (first self compiled)

Applicant before: GUANGDONG XIANGXUE LIFE SCIENCES, Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant